Fig. 3From: Quality by design approach for development and validation of a RP-HPLC method for simultaneous estimation of xipamide and valsartan in human plasmaPareto chart showing factors effect on: (A) retention time (VAL) and (B) resolution between XIP and valsartan (VAL)Back to article page